We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-22.83%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
-$590M
Cap. Flow
-$271M
Cap. Flow %
-26.22%
Top 10 Hldgs %
52.21%
Holding
94
New
6
Increased
10
Reduced
22
Closed
23

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$19.6M
2
NVDQ
Novadaq Technologies Inc.
NVDQ
+$18.9M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$18.4M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$14.8M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$7.38M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$91.5M
2
NVRO
NEVRO CORP.
NVRO
+$31.5M
3
EBS icon
Emergent Biosolutions
EBS
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$22.9M
5
ATRC icon
AtriCure
ATRC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 70.61%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDWD icon
51
MediWound
MDWD
$183M
$4.29M 0.41%
75,855
– –
ANTH
52
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$4.18M 0.4%
144,334
– –
MRTX
53
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.15M 0.4%
193,863
-42,007
-18% -$939K
TENX icon
54
Tenax Therapeutics
TENX
$385M
$4.04M 0.39%
62
– –
CASM
55
DELISTED
CAS Medical Systems, Inc.
CASM
$3.54M 0.34%
2,494,534
-123,762
-5% -$201K
NVET
56
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$3.3M 0.32%
1,000,000
+278,405
+39% +$908K
CRDC
57
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$3.16M 0.31%
887,499
– –
SCYX icon
58
SCYNEXIS
SCYX
$37M
$3.04M 0.29%
9,417
-271
-3% -$103K
EPRS
59
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$2.9M 0.28%
1,079,543
-295,457
-21% -$829K
CFRX
60
DELISTED
ContraFect Corporation
CFRX
$2.87M 0.28%
1,056
-717
-40% -$2.03M
PLX icon
61
Protalix BioTherapeutics
PLX
$191M
$2.85M 0.27%
338,629
+4,772
+1% +$40.9K
CDTX
62
DELISTED
Cidara Therapeutics
CDTX
$2.12M 0.2%
8,344
– –
TNXP icon
63
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
ARDX icon
64
Ardelyx
ARDX
$1.24B
$1.68M 0.16%
216,180
-133,110
-38% -$1.31M
PHIO icon
65
Phio Pharmaceuticals
PHIO
$12.1M
$1.35M 0.13%
8
-1
-11% -$176K
WINT
66
DELISTED
Windtree Therapeutics Inc
WINT
$1.3M 0.13%
777,797
-1
-0% -$2
SPNC
67
DELISTED
Spectranetics Corp
SPNC
$1.05M 0.1%
72,615
-492,464
-87% -$6.82M
SSKN
68
DELISTED
Strata Skin Sciences
SSKN
$953K 0.09%
20,166
-5,320
-21% -$275K
AIXC
69
AIxCrypto Holdings Inc
AIXC
$16.6M
$879K 0.08%
6
– –
VCYT icon
70
Veracyte
VCYT
$4.52B
$525K 0.05%
97,298
-207,682
-68% -$1.23M
AMPH icon
71
Amphastar Pharmaceuticals
AMPH
$825M
– –
-1,026,979
Closed -$14.6M
ARMP icon
72
Armata Pharmaceuticals
ARMP
$171M
– –
-3,943
Closed -$2.2M
ASRT
73
DELISTED
Assertio
ASRT
– –
-12,093
Closed -$13.2M
ATRC icon
74
AtriCure
ATRC
$1.77B
– –
-803,519
Closed -$18M
BHC icon
75
CALL
Bausch Health
BHC
$1.65B
– –
-100,000
Closed -$10.2M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Broadfin Capital held 94 positions worth $1.04B, down 36% from $1.63B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $271M in Q1 2016, closing 23 positions and reducing 22 holdings. Its most notable exit was Bausch Health, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 79% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Aralez Pharmaceuticals Inc. worth $13.5M.

  • Broadfin Capital's largest Q1 2016 buy was Aralez Pharmaceuticals Inc.: 3,800,000 shares worth $13.5M.
  • Broadfin Capital added most to Novadaq Technologies Inc. in Q1 2016, an estimated $18.9M increase.
  • Broadfin Capital's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $31.5M.
  • Broadfin Capital fully exited Bausch Health in Q1 2016, selling an estimated $91.5M.
  • Broadfin Capital's ten largest holdings make up 52% of its $1.04B portfolio in Q1 2016.
  • Broadfin Capital opened 6 new positions and closed 23 in Q1 2016.
  • Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $1.04B.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.